A multi-country evaluation of neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages 1096-1101

  Hoiseth, Susan K ^a   Murphy, Ellen ^a   Andrew, Lubomira ^a   Vogel, Ulrich ^b   Frosch, Matthias ^b   Hellenbrand, Wiebke ^c   Abad, Raquel ^d   Vazquez, Julio A ^d   Borrow, Ray ^e   Findlow, Jamie ^e   Taha, Muhamed Kheir ^f   Deghmane, Ala Eddine ^f   Caugant, Dominique A ^g   Kriz, Paula ^h   Musilek, Martin ^h   Mayer, Leonard W ⁱ   Wang, Xin ⁱ   MacNeil, Jessica R ⁱ   York, Laura ^a   Tan, Charles Y ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a   more..

^a PFIZER INC   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f INSTITUT PASTEUR   (France)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Epidemiology; Factor H binding protein; Meningococcal; Serogroup B vaccine

Indexed keywords

BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; CROSS PROTECTION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; INFANT; MENINGOCOCCOSIS; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE ANALYSIS; SPAIN; STOP CODON; VULNERABLE POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; EUROPE; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; UNITED STATES;

EID: 84891825945     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829aa63b     Document Type: Article

References (47)

1. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138: 4402-4407.
2. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2: 355-357.
3. Häyrinen J, Jennings H, Raff HV, et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis. 1995;171: 1481-1490.
4. Caron F, du Châtelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11: 455-463.
5. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(suppl 2):B3-12.
6. Martin SL, Borrow R, van der Ley P, et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine. 2000;18: 2476-2481.
7. Findlow J, Lowe A, Deane S, et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine. 2005;23: 2623-2627.
8. Riedmann EM. Human vaccines and immunotherapeutics: news. Hum Vaccin Immunother. 2013;9: 7-10.
9. Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines. 2011;10: 617-634.
10. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51: 1127-1137.
11. Richmond PC, Marshall HS, Nissen MD, et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12: 597-607.
12. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA 1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177: 501-510.
13. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176: 7566-7575.
14. Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun. 2009;77: 292-299.
15. Schwarz R, Seibel PN, Rahmann S, et al. Detecting species-site dependencies in large multiple sequence alignments. Nucleic Acids Res. 2009;37: 5959-5968.
16. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72: 2088-2100.
17. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200: 379-389.
18. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology. 2009;155(Pt 9): 2873-2883.
19. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA 1870. JExp Med. 2003;197: 789-799.
20. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28: 6086-6093.
21. Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30: 6163-6174.
22. Richmond P, Marshall H, Sheldon E, et al. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. In: 17th International Pathogenic Neisseria Conference, Banff, Alberta, Canada, 2010.
23. Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31: 1061-1068.
24. Sheldon EA, Schwartz H, Jiang Q, et al. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012;8: 888-895.
25. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection- serum bactericidal antibody activity. Vaccine. 2005;23: 2222-2227.
26. Jansen KU. Prospects for prevention of meningococcal B disease. In: Meningitis Research Foundation Conference, London, UK, 2011.
27. Centers for Disease Control and Prevention. Active bacterial core surveillance (updated June 4, 2012). Available at: http://www.cdc.gov/abcs/ reports-findings/surv-reports.html. Accessed August 12, 2013.
28. Schrauder A, Claus H, Elias J, et al. Capture-recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003. Epidemiol Infect. 2007;135: 657-664.
29. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11: 595.
30. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50: 184-191.
31. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29: 4739-4744.
32. Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003;31: 3497-3500.
33. Tamura K, Dudley J, Nei M, et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24: 1596-1599.
34. Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6:e1001027.
35. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195: 1445-1454.
36. Snyder LA, Butcher SA, Saunders NJ. Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology. 2001;147(Pt 8): 2321-2332.
37. Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18: 1002-1014.
38. Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin. 2011;7(suppl): 68-74.
39. Seib KL, Oriente F, Adu-Bobie J, et al. Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine. 2010; 28: 2416-2427.
40. de Filippis I, de Lemos AP, Hostetler JB, et al. Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil. PLoS One. 2012;7:e33016.
41. Mothibeli KM, du Plessis M, von Gottberg A, et al. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine. 2011;29: 2187-2192.
42. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17: 840-847.
43. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326: 365-366.
44. Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197: 737-743.
45. Marsh JW, Shutt KA, Pajon R, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine. 2011;29: 6049-6058.
46. Anderson AS, Hao L, Jiang Q, et al. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum Vaccin Immunother. 2013;9: 471-479.
47. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004;42: 5146-5153.